I-SPY
Phase 2 Recruiting
5,000 enrolled
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Phase 1/2 Recruiting
139 enrolled
TTI-621-03
Phase 2 Terminated
76 enrolled 53 charts
ImmunoSarc
Phase 1/2 Completed
197 enrolled
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Phase 2 Completed
73 enrolled 11 charts
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
Phase 1 Completed
16 enrolled
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Phase 3 Completed
588 enrolled 22 charts
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Phase 1 Completed
30 enrolled
Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
Phase 3 Completed
455 enrolled
Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
Phase 3 Completed
350 enrolled
Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma
Phase 2 Unknown
118 enrolled
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma
Phase 2/3 Terminated
133 enrolled
Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
Phase 2 Completed
Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
Phase 3 Completed
340 enrolled
Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
Phase 3 Completed
780 enrolled